Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men

摘要: Objective  To determine the effects of terazosin on blood pressure and antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH). Patients methods Safety data from a large, multinational study were analysed retrospectively. Normotensive hypertensive patients received escalating dosages for 10 weeks maintained 5 or 10 mg daily doses 16 (single-blind period). After initial treatment period, only men having sufficient improvements International Prostate Symptom Score (≥30%) peak flow rate (≥10%) randomly assigned to continue receive placebo 24 (double-blind period). Results In patients, reduced systolic (SBP) diastolic (DBP) during single-blind period; these clinically significant reductions receiving double-blind period. However, normotensive controlled produced no mean changes SBP DBP either Terazosin did not adversely affect concomitant medication. Conclusion Terazosin is safe BPH men, including who are already taking additional drugs.